In the Western world, LinkedIn is a staple for many recruitment professionals. It has proven to be a powerful tool for networking, talent sourcing and job postings. But in Japan, people don’t use LinkedIn very much.Here’s why LinkedIn isn’t popular…
HOME > BUSINESS
BUSINESS
- Former Nycomed CSO to Head General Medicine Drug Discovery Unit of Takeda
October 24, 2012
- COPD Treatment Market to Expand 2.8 Times by 2020 Compared to 2011: Fuji-Keizai
October 24, 2012
- Antiepileptic Drug Fycompa Approved in the US: Eisai
October 24, 2012
- Astellas Launches Mirabegron in US
October 24, 2012
- Astellas Poised for Domestic PIIb Trial of Novel IBS Treatment
October 23, 2012
- Astellas Receives Recommendation for Approval of Mirabegron in Europe
October 23, 2012
- Neuropathic Pain Treatment Offered Funding from JST’s Support Program: Nippon Chemiphar
October 23, 2012
- Astellas Launches Gonax for Full-Fledged Entry into Cancer Field
October 23, 2012
- Takeda Moves Up to 5th, Pfizer 1st in Patent Assets Ranking
October 22, 2012
- Chugai Succeeds in Establishing World's First Stable Cancer Stem Cell Lines
October 22, 2012
- MTPC to Dissolve Capital Alliance with Choseido
October 22, 2012
- Kyowa Kirin Suspends PIIa Study of RTA 402 in Response to Licensor’s Termination of Study
October 22, 2012
- Nexium Dominates No.1, 2 Positions in Both GP, HP Markets in September Prior to Lifting of Ban on Long-Term Prescription: RepTrack Survey
October 19, 2012
- 40% of Doctors Collect Drug Information Via Smartphones: CareNet Survey
October 19, 2012
- Novartis Files for Additional Indication of Pediatric Use for Xolair
October 18, 2012
- Ajinomoto Files NDA for AJH801, 6th Fixed-Dose ARB/CCB Combination in Japan
October 18, 2012
- Qol’s Mr Takada Hints at Continued Use of Long-Listed Drugs from Makers Hiring Apo Plus MRs
October 17, 2012
- Asklep to Set Up 3rd East Asian Subsidiary in South Korea
October 17, 2012
- Denosumab Significantly Reduces Vertebral Fractures in Osteoporosis Patients in PIII Study: Daiichi Sankyo
October 17, 2012
- Asahi Glass Offers CMO Services to Biopharmaceutical Industry Using ASPEX Technology: Dr Kumagai
October 17, 2012
ページ
An increasing number of companies in Japan are showing an eagerness to snatch up “drug loss” assets. As of this…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…